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SYNOPSIS 
Maintenance of a topological homeostasis by introduction and removal of the supercoils to 
relieve excessive strain on the DNA is a hallmark of topoisomerase function in the cell. The 
requirement of the topoisomerases during DNA transaction processes marks a ubiquitous 
presence of the enzymes in all the life forms. Different reactions carried out by the enzymes 
include relaxation of positive and negative supercoils required majorly during DNA replication 
and transcription, decatenation at the end of DNA replication to separate the daughter 
chromosomes and removal of lethal knots generated in the circular chromosome. In eubacteria, 
the enzymes introduce negative supercoils to facilitate easier strand separation for DNA 
transaction processes. However, in thermophiles, a different enzyme maintains the genome in a 
positively supercoiled form to protect from denaturation by excessive heat. These varied 
functions are carried out by different topoisomerases. Therefore, each organism maintains a 
minimum required set of the enzymes and the absence of a certain enzyme may be compensated 
for by topoisomerases with dual functions. For example, Mycobacterium tuberculosis and many 
other slow growing mycobacteria do not possess topoisomerase IV or its homologs. In these 
organisms, the DNA gyrase is suggested to carry out both negative supercoiling and decatenation 
reactions. Therefore, the mycobacterial DNA gyrase must be able to manage between both the 
functions in vivo. In contrast, Mycobacterium smegmatis and few other mycobacteria contain an 
additional type II topoisomerase which does not resemble any known type II enzyme but could 
catalyze relaxation and decatenation reactions. Importantly, the enzyme displays a unique ability 
to introduce limited positive supercoils and may have certain functions inside the cell which 
remains to be studied. Owing to the indispensability for bacterial survival topoisomerases present 
themselves as important drug targets. A large number of inhibitors have been found to inhibit the 
enzyme and thereby killing the bacterial. Among these, quinolones are successfully being used 
as broad spectrum antibacterial drugs. Although the commonly used quinolones inhibit many 
bacterial pathogens, a reduced susceptibility is exhibited by some of the pathogens e.g. 
Mycobacterium tuberculosis. To circumvent the lower efficacy of existing drugs, new and 
modified quinolones have been developed which are highly effective against mycobacteria. The 
difference in the susceptibility may be conferred by a difference in the chemical property of the 
drug and the interacting residues present in the enzyme.  
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In the present thesis efforts have been made to understand the mechanism of the type II 
topoisomerases from mycobacteria and drug action on these enzymes. The thesis is divided into 
four chapters. In Chapter I of the thesis an introduction is provided on the topoisomerases, their 
classification and different reactions catalyzed by these enzymes. As the work in present thesis 
has been carried out with type II topoisomerases, introduction of type II enzymes, their structure 
and mechanisms is elaborated.  DNA gyrase, its mechanism of reaction and in vitro and in vivo 
functions are explained in great detail. DNA gyrase and topoisomerase IV are targeted by a range 
of different inhibitors. These different classes of inhibitors and their mechanism of action are 
described. Finally, the mechanism of mycobacterial DNA gyrase with structural information and 
the current understanding of quinolone action on the enzyme are explained. The chapter ends 
with the objective of the study in the present thesis. In chapter II, the studies are aimed at 
understanding the molecular basis for decatenation carried out by mycobacterial DNA gyrase. 
Previous work from the laboratory showed that the enzyme can carry out decatenation more 
efficiently than its homolog from E. coli. It was shown that the mycobacterial enzyme binds two 
DNA molecules in trans in a length dependent manner. The ability to bind the second DNA is 
conferred upon the holoenzyme by ATPase subunit (GyrB) subunit which alone can bind DNA. 
Similar studies using topo IV from E. coli, the strongest known decatenase showed binding of 
two DNA molecules and the second DNA binding by ATPase (ParE) subunit.  However, GyrB 
subunit from E. coli DNA gyrase, a weaker decatenase, does not bind second DNA molecule 
efficiently. The results provide a general mechanism for decatenation by type II enzymes in 
which efficient binding of second DNA is important.  
In Chapter III, studies have been carried out using topo NM, an atypical type II topoisomerase 
from Mycobacterium smegmatis. The enzyme has been characterized previously in the 
laboratory. In addition to efficient decatenation and relaxation, the enzyme exhibits a unique 
ability to introduce positive supercoils into the DNA. As demonstrated for the mycobacterial 
DNA gyrase and topo IV in the Chapter II, the ATPase subunit (Topo N) of topo NM, binds 
second DNA efficiently. The binding of both gate and transport segments increases with the 
length of the DNA. Binding of two DNA molecules by the holoenzyme appears to be a 
cumulative effect of DNA binding to individual subunits.  In the absence of any inhibitor, the 
enzyme accumulates cleaved DNA products with shorter DNA but not with larger DNA. The 
cleavage of the shorter DNA is supported only in the presence of Mg2+ and Mn2+. Another 
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important property of the enzyme is to introduce positive supercoils which appears to be due to 
its efficient utilization of ATP and a high rate of reaction.  
Chapter IV deals with the interaction of mycobacterial gyrase with fluoroquinolones (FQs). 
Although DNA gyrase is the sole target of the FQs in M. tuberculosis, the lower susceptibility to 
commonly used FQs have led to the studies to find out more effective quinolones. Previous 
studies from the laboratory showed a lower susceptibility of the mycobacterial gyrase to 
ciprofloxacin, but moxifloxacin could inhibit the enzyme efficiently. The better inhibition by 
moxifloxacin appears to be due to efficient trapping of the enzyme-DNA covalent complex. Both 
ciprofloxacin and moxifloxacin bind the DNA gyrase from mycobacteria, E. coli and E. coli topo 
IV, independent of DNA. The extent of binding also correlates with the inhibition potential of 
the drug against a given enzyme. A general model of quinolone enzyme interaction is provided 
wherein the quinolones are shown to interact with GyrA subunit or holoenzyme or the enzyme-
DNA complex which would finally result in the trapping of the covalent complex.  
  
